(DAKT - - $16.12) 26, 2003 DAKT

Size: px
Start display at page:

Download "(DAKT - - $16.12) 26, 2003 DAKT"

Transcription

1 Dennis Nielsen (612) Consumer Products - Durables August 26, 2003 Financial Summary Rev (mil) A 2004E July $40.2 $44.1 $48.9A Oct $41.6 $48.1 $54.8E Jan $30.9 $38.2 $43.6E April $36.1 $47.4 $54.3E FY $148.8 $177.8 $201.6E P/Sales 2.0x 1.7x 1.5x EPS A 2004E July $0.08 $0.16 $0.22A Oct $0.10 $0.21 $0.20E Jan ($0.02) $0.10 $0.11E April $0.08 $0.17 $0.21E FY $0.25 $0.64 $0.74E P/E 64.4x 25.2x 21.8x Price: $ Week Range: $19.38-$8.55 Target: $22 Rating: BUY Shares Outstanding: 18.6 mil Float: 13.5 mil Mkt. Capitalization: $300 mil Avg. Volume: 123,800 Instit. Ownership: 37% BV / Share $3.74 Debt / Tot. Cap.: 6.2% Est. LT EPS Growth: 20% Exp. Next Rpt. Date: 11/20 Company Description Daktronics, Inc. designs, manufactures, sells and services dynamic visual communication systems for customers worldwide. Since inception in 1968, the Company has installed tens of thousands of scoreboards and display systems in more than 70 countries. Daktronics, Inc. (DAKT - $16.12) DAKT reports record Q1 results. BUY Key Points: Q1 revenue increased 11% to record $48.9 million. Q1 earnings increased 38% to $4.3 million, also record quarterly net income. Reported EPS of $0.22 was ahead of guidance of $0.13 to $0.19. Backlog was up sharply to $56 million from $50 million at year-end and at Q Guidance remains for FY 2004 revenues to increase to a range of $195 to $210 million, up 10% to 18% from We expect earnings to increase accordingly. Q2 guidance is for revenues to increase to $50 to $55 million with EPS in a range of $0.15 to $0.22 compared to last year s $48 million and $0.21. We raised our FY 2004 EPS estimate a penny to $0.74. Our price target remains $22 based on a P/E multiple of 30x our FY04 (April) EPS estimate of $0.74. Investment Recommendation: Daktronics reported Q1 results that set records for the period and exceeded our estimates. Revenue for the period increased 11% to $48.9 million slightly below our estimate. Net income for the quarter, however, improved to $4.3 million vs. $3.1 million a year ago. EPS of $0.22 was up 34% compared to last year s result and ahead of our estimate of $0.18. The net income margin was a record 8.8% in Q Daktronics continued to receive strong order flow. Backlog at the end of Q1 was $56 million compared to $50 million at the end of Q4. The Company announced several high-profile sports applications, including major league football sites. The backlog includes transportation and commercial application orders as well. Guidance for FY2004 was not changed and the company expects revenues to increase 10% to 18% and earnings to increase accordingly. During Q1, the Company paid off over $3 million in long-term debt, and increased cash by $2 million. We are impressed by the strength of the Company s business and have raised our FY04 EPS estimate. The stock is rated BUY with a 12-month price target to $22. Source: Reuters Feltl and Company Research Department. 120 South Sixth Street, Suite 2600 Minneapolis, MN Please see important disclosures at end of report.

2 First Quarter FY2004 Results Daktronics reported record first quarter sales and earnings for the period ended August 2, Revenues for the 13-week period increased 11% to $48.9 million. Net income increased 38% to $4.3 million, or $0.22 per share, versus $3.1 million, or $0.16 per share, a year ago. Both sales and net income were records for any quarter in the company s history. EPS guidance for the quarter was $0.13 to $0.19. First quarter sales included several major league sport display systems for Lambeau Field, Soldier Field in Chicago and the new home of the Philadelphia Eagles, among others. Commercial backlog increased with the booking of standard products and large horse racing systems in California and Paris. Gross margin for Q1 increased 100 basis points to 35.7% of sales compared to the period a year ago. Sequentially, gross margin increased 260 basis points compared to Q4. The Company continued to enjoy lower raw materials costs during the quarter, but attributed the strong gross margin to excellent on-site installation management on several large systems. Going forward, we look for gross margins to decline modestly, but remain above 30%. Operating expenses of $10.8 million increased 4.5% from the comparable period a year ago, but declined as a percent of sales. General & administrative, and product design & development expenses each increased as a percent of sales compared to the year ago period while selling expenses declined. The operating margin for Q was 13.7% of sales compared to 11.4% for Q1 in The net margin for Q was an all-time record 8.8% of sales. Daktronics ended the quarter with a backlog of $56 million compared to a backlog of $50 million at the end of the year. The first quarter marked the 6 th consecutive quarter with a backlog of $50 million or more. The Company continued to strengthen its balance sheet during the quarter. Long-term debt, including the current portion, was reduced $3.7 million to $4.6 million, down from $13.8 million in April Long-term debt represents 6.2% of total capital, down from 21.2% at that time. Daktronics ended the quarter with $11.2 million in cash up from $9.3 million at fiscal year-end. Working capital was $39.3 million. Outlook & Valuation The company provided guidance for Q2 and for fiscal year 2004 with the Q1 earnings release. Sales for the second quarter are expected to be in a range of $50 to $55 million, with earnings in the range of $0.15 to $0.22 per share. For the year, revenues are expected to be in the range of $195 to $210 million, up 11% to 18% over the FY 2003 results. The company went on to say that earnings are expected to increase accordingly, despite slightly lower projected gross margins. Our model for the fiscal year 2004 has been revised to conform to the guidance provided by the company. We expect the company to continue to demonstrate solid growth in the sports and transportation sectors of their business with improving contribution from the commercial sector as the economy improves. The company derives approximately two-thirds of sales from the sports market, approximately 15% from the commercial sector and 10% from transportation. The balance is derived from service, primarily. Page2 Daktronics, Inc. (DAKT) 8/26/03

3 The company has guided expectations for slightly lower gross margins in 2004 than seen in Favorable pricing on some projects and some raw materials seen in 2003 are not expected to be repeated in the coming year. Nonetheless, we expect overall operating profit margins to advance slightly with continued expense management and operating leverage. Our forecast is for sales to advance about 13% to $201.6 million and operating margins to increase to 11.5% in 2004 from 11.2% for Net income is expected to reach $14.7 million, up 18%, and EPS is projected at $0.74 compared to $0.64 reported for Valuation Method for Determining Price Target Our 12-month price target of $22 is based on the stock trading at 30 times our FY04 EPS estimate of $0.74. DAKT currently trades at 21.8 times projected FY04 EPS. We think the stock can support a premium valuation to its growth rate based on its leadership position, solid operating performance, the diverse markets it serves and its ongoing investment in technology. Risks To Achievement of Price Target The computer-programmable information display industry is highly fragmented and intensely competitive in certain markets. There are several established manufacturers of competing products who may have greater market penetration in certain markets or greater financial resources than Daktronics. The Company s products are often included in their customers marketing budgets, therefore, to some extent, the Company can be competing at times with other forms of advertising, such as television, print media or fixed display signs. Daktronics backlog includes customer sales agreements and purchase orders that it expects to complete within 12 months. However, sales agreements and purchase orders are subject to cancellation or delay with little or no penalty, backlog is not necessarily indicative of future net sales. The Company has found areas, both domestically and internationally, that prevent or restrict the installation of outdoor signs and computer-programmable information displays. These concerns are generally related to aesthetics or driver safety if an animated or moving display is located near a road or highway. These factors may prevent or limit the Company from selling products in certain areas. Readers should recognize that the risks noted here or referenced do not represent a comprehensive list of all risk factors or potential issues, nor all factors that may preclude price target achievement. Additional risk factors exist and are outlined in the Company s SEC filings. Analyst Certification I, Dennis Nielsen, certify that the views expressed in this research report accurately reflect my personal views about the subject company and its securities. I also certify that I have not been, am not, and will not be receiving direct or indirect compensation related to the specific recommendations expressed in this report. Page3 Daktronics, Inc. (DAKT) 8/26/03

4 Daktronics, Inc. Summary Financials Source: Company reports and Feltl and Company. FY01 FY02 Q1A Q2A Q3A Q4A FY03A Q1A Q2E Q3E Q4E FY04E Figures in (000) expcept per share amts. 8/3/02 11/2/02 2/1/03 5/3/03 8/3/03 11/2/03 2/1/04 5/3/04 Net Sales $152,331 $148,773 $44,107 $48,074 $38,220 $47,364 $177,764 $48,918 $54,800 $43,600 $54,300 $201,618 % change in sales 23.5% -2.3% 9.6% 15.6% 23.8% 31.2% 19.5% 10.9% 14.0% 14.1% 14.6% 13.4% Cost of Sales: 107, ,741 28,783 32,288 25,855 31, ,633 31,468 37,264 29,648 36, ,304 Gross Profit 45,221 45,032 15,324 15,786 12,365 15,657 59,131 17,450 17,536 13,952 17,376 66,314 Selling 18,805 22,009 6,807 5,974 5,868 6,317 24,966 6,429 6,700 6,500 6,600 26,229 General & Administrative 6,280 6,478 1,652 1,683 1,824 2,263 7,422 2,122 2,200 1,840 1,934 8,096 Product Design & Development 5,685 7,442 1,830 1,721 1,534 1,833 6,918 2,205 2,400 2,100 2,120 8,825 Operating Income 14,451 9,103 5,035 6,408 3,139 5,244 19,825 6,694 6,236 3,512 6,722 23,164 Non-Operating Income (Expense) Interest Income Interest Expense (1,599) (1,542) (255) (226) (195) (222) (897) (234) (150) (150) (150) (684) Other 346 (242) Income Before Income Taxes 13,965 8,142 5,158 6,401 3,186 5,851 20,596 7,131 6,356 3,632 6,842 23,961 Income tax provision 5,275 3,245 2,024 2,376 1,288 2,419 8,107 2,812 2,447 1,398 2,634 9,292 Minority interest in inc. of subsidiary (10) (21) (31) (11) (11) Net Income $8,685 $4,892 $3,134 $4,025 $1,888 $3,411 $12,458 $4,308 $3,909 $2,234 $4,208 $14,658 % change in N.I. 39.5% -43.7% 99.1% 99.7% n.m % 154.7% 37.5% -2.9% 18.3% 23.4% 17.7% Diluted earnings per share $0.46 $0.25 $0.16 $0.21 $0.10 $0.17 $0.64 $0.22 $0.20 $0.11 $0.21 $0.74 % change in EPS 36.1% -44.7% 100.8% 98.7% n.m % 151.0% 33.9% -5.4% 17.4% 22.2% 15.7% Weighted average shares 18,874 19,230 19,292 19,308 19,697 19,739 19,514 19,804 19,825 19,850 19,925 19,850 % of Sales: Cost of Sales 70.3% 69.7% 65.3% 67.2% 67.6% 66.9% 66.7% 64.3% 68.0% 68.0% 68.0% 67.1% Gross Profit 29.7% 30.3% 34.7% 32.8% 32.4% 33.1% 33.3% 35.7% 32.0% 32.0% 32.0% 32.9% Selling 12.3% 14.8% 15.4% 12.4% 15.4% 13.3% 14.0% 13.1% 12.2% 14.9% 12.2% 13.0% General & Administrative 4.1% 4.4% 3.7% 3.5% 4.8% 4.8% 4.2% 4.3% 4.0% 4.2% 3.6% 4.0% Product Design & Development 3.7% 5.0% 4.1% 3.6% 4.0% 3.9% 3.9% 4.5% 4.4% 4.8% 3.9% 4.4% Operating Income 9.5% 6.1% 11.4% 13.3% 8.2% 11.1% 11.2% 13.7% 11.4% 8.1% 12.4% 11.5% Net Income 5.7% 3.3% 7.1% 8.4% 4.9% 7.2% 7.0% 8.8% 7.1% 5.1% 7.7% 7.3% Tax Rate 37.8% 39.9% 39.2% 37.1% 40.4% 41.3% 39.4% 39.4% 38.5% 38.5% 38.5% 38.8% Backlog at period end $51,000 $50,000 $51,000 $51,000 $50,000 $50,000.0 $56,000 Balance Sheet Data: Cash & cash equivalents $2,896 $2,097 $3,232 $8,991 $8,863 $9,277 $11,182 Accounts receivable $21,090 $17,878 $24,670 $19,410 $15,274 $25,912 $24,716 Inventories $19,719 $16,472 $18,482 $16,248 $17,018 $14,863 $17,827 Working capital $26,967 $28,353 $32,333 $37,079 $37,453 $39,700 $39,307 Long-term debt $10,344 $9,574 $8,947 $7,631 $5,926 $8,400 $4,628 Shareholders' equity $45,823 $51,501 $54,816 $58,900 $61,146 $65,303 $69,864 Book value $2.55 $2.82 $2.99 $3.21 $3.32 $3.52 $3.74 Page4 8/26/03

5 Feltl and Company Rating System: Feltl and Company utilizes a four tier rating system for potential total returns over the next 12 months, and a three-tier system for risk assessment. Potential Total Return Assessment Strong Buy: The stock is expected to have total return potential of at least 30%. Catalysts exist to generate higher valuations, and positions should be initiated at current levels. Buy: The stock is expected to have total return potential of at least 15%. Near term catalysts may not exist and the common stock needs further time to develop. Investors requiring time to build positions may consider current levels attractive. Hold: The stock is expected to have total return potential of less than 15%. Fundamental events are not present to make it either a Buy or a Sell. The stock is an acceptable longer-term holding. Sell: Expect a negative total return. Current positions may be used as a source of funds. Related Risk Assessment Speculative: Business and financial risks are significantly greater than the market risk. The company has an inconsistent operating history and the share price may have significant volatility. Aggressive: Business and financial risks are higher than the market risk. The company has a history of revenue growth and/or operating profits. The share price may be more volatile than the general market. Market: Business and financial risks are in line with the general market. Disclosure Statement The information contained in this report is based on sources considered to be reliable, but not guaranteed, to be accurate or complete. Any opinions or estimates expressed herein reflect a judgment made of this date, and are subject to change without notice. This report has been prepared solely for informative purposes and is not a solicitation or an offer to buy or sell any security. The securities described may not be qualified for purchase in all jurisdictions. Because of individual requirements, advice regarding securities mentioned in this report should not be construed as suitable for all accounts. This report does not take into account the investment objectives, financial situation and needs of any particular client of Feltl and Company. Some securities mentioned herein relate to small speculative companies that may not be suitable for some accounts. Feltl and Company suggests that prior to acting on any of the recommendations herein, the recipient should consider whether such a recommendation is appropriate given their investment objectives and current financial circumstances. Past performance does not guarantee future results. Conflicts of Interest Investors should assume that Feltl and Company is seeking or will seek investment banking or other business from the companies in our research universe. From time to time, Feltl and Company, or its officers, directors or agents, or members of their families, may have a position in securities mentioned and may make purchases or sales of the same in the open market or otherwise, and may own options, rights or warrants to purchase the same. Feltl and Company may be a market maker and may act as principal or agent with respect to the sale or purchase of securities mentioned, and may have managed or co-managed a public offering of the securities mentioned within the last three years. Additional information is available upon request. Feltl & Company does make a market in the subject security at the date of publication of this report. As a market maker, Feltl & Company could act as principal or agent with respect to the purchase or sale of those securities. As of the end of the month preceding the date of publication of this report, Feltl & Company did not beneficially own 1% or more of any class of common equity securities of the subject company. Feltl & Company has not been engaged for investment banking services with the subject company during the past twelve months and does not anticipate receiving compensation for such services in the next three months. The analyst or any member of his/her household does not hold a long or short position, options, warrants, rights or futures of this security in their personal account(s). The analyst has not received any compensation for any investment banking business with this company in the past twelve months and does not expect to receive any in the next three months. Page5 8/26/03

6 No director, officer or employee of Feltl & Company serves as a director, officer or advisory board member to the subject company. Feltl & Company has not served as a broker, either as agent or principal, buying back stock for the subject company s account as part the company s authorized stock buy-back program in the last twelve months. Feltl & Co. may possibly serve as the company s broker, either as agent or principal, as part of the company s authorized buy-back program in the next three months. There is not any actual material conflict of interest that either the analyst or Feltl and Company is aware of. Feltl and Company Ratings Distribution Ratings Distribution for Feltl & Co. 8/26/03 Hold 17% Sell 3% SB/Buy 80% Feltl and Company provided investment banking services for 4% of the research covered companies over the last twelve months, of which one was rated Buy/Strong Buy and none were rated Hold. Buy-1/30/03 $18 Pr.Tgt. Buy-2/20/03 $19 Price Tgt. Buy-6/05/03 $22 Pr. Tgt. Buy-8/26/03 $22 Pr. Tgt. Date Nature of Report Rating Price Target 1/30/03 Coverage Initiated BUY $17-$19 2/20/03 Quarterly update BUY $18-$20 6/05/03 Quarterly update BUY $22 8/26/03 Quarterly update BUY $22 Page6 8/26/03

7 EQUITY CAPITAL MARKETS DIRECTORY RESEARCH DEPARTMENT Ernest W. Andberg, CFA Dennis E. Nielsen, CFA Richard A. Ryan (612) Joseph P. Sullivan, CFA (612) INSTITUTIONAL SALES: (866) Thomas Pierce Senior Vice President Institutional Sales (612) Mark Hagen (612) Paul M. Manley Ryan Quade (612) TRADING: (866) Jo Pihl Senior Vice President (612) James G. Fredericks Vice President Manager, Equity Trading (612) Joseph G. Fredericks (612) Daniel L. Hennen (612) William W. Koop (612) Deborah L. Zieman Institutional Sales Trading (612) /03/ SOUTH SIXTH STREET SUITE 2600 MINNEAPOLIS, MINNESOTA (612) (866) MEMBER SIPC & NASD

Micro Component Technology (MCTI - $0.43) Q4 Results Below Estimates Key Points:

Micro Component Technology (MCTI - $0.43) Q4 Results Below Estimates Key Points: Richard A. Ryan raryan@feltl.com (612) 492-8841 Semiconductor Cap. Equipment February 17, 2005 Financial Summary Rev(mil) 2003 2004 2005E Mar $ 2.2 $ 4.3 $2.3E Jun $ 2.3 $ 4.2 $2.8E Sep $ 2.9 $ 3.9 $3.5E

More information

MINE SAFETY APPLIANCES CO. (MSA - $63.27) Q3 Better Than Expected BUY Aggressive

MINE SAFETY APPLIANCES CO. (MSA - $63.27) Q3 Better Than Expected BUY Aggressive Richard A. Ryan raryan@feltl.com (612) 492-8841 Safety Equipment Manufacturer November 6, 2003 Financial Summary Rev 2002 2003E 2004E (mil) March $128.1 $160.4A $175.1E June $141.9 $176.4A $192.0E Sept.

More information

Stellent, Inc. (STEL - $8.59)

Stellent, Inc. (STEL - $8.59) Richard A. Ryan raryan@feltl.com (612) 492-8841 Enterprise Software August 7, 2006 Financial Summary Rev(mil) 2005 2006 2007E Jun $22.3 $28.6 $32.3A Sep $28.0 $30.1 $33.4E Dec $27.7 $31.7 $34.8E Mar $28.5

More information

Astronics Corporation (ATRO - $16.35) Coverage terminated.

Astronics Corporation (ATRO - $16.35) Coverage terminated. Richard A. Ryan raryan@feltl.com (612) 492-8841 Aerospace Supplier May 12, 2008 Financial Summary Rev(mil) 2007 2008E 2009 Mar $ 42.9 $ 41.1 - Jun $ 41.4 - Sep $ 37.7 - Dec $ 36.3 - FY $158.2 P/Sales 0.8x

More information

Domino s Pizza, Inc.

Domino s Pizza, Inc. Feltl and Company Research Department 225 South Sixth Street, Suite 4200 Minneapolis, MN 55402 1.866.655.3431 Mark E. Smith mesmith@feltl.com 612.492.8806 Domino s Pizza, Inc. Company Description: Domino

More information

Compex Technologies, Inc. (CMPX - $4.89)

Compex Technologies, Inc. (CMPX - $4.89) Ernest W. Andberg, CFA ewandberg@feltl.com (612) 492-8836 Medical Devices February 10, 2005 Financial Summary Rev(mil) 2004 2005E 2006E Sep $19.2 $21.7A $ Dec $22.5 $25.2A $ Mar $21.7 $24.6 $ Jun $22.7

More information

Hibbett Sports Inc. (HIBB - $50.89) BUY

Hibbett Sports Inc. (HIBB - $50.89) BUY Hibbett Sports Inc. Company Description: Hibbett Sports Inc. operates 848 sporting goods stores in the United States with most stores located in the Southeast. Hibbett is a full service sporting goods

More information

American Vanguard (AVD - $25.01) STRONG BUY

American Vanguard (AVD - $25.01) STRONG BUY American Vanguard American Vanguard is a small but rapidly growing manufacturer and marketer of crop protection products like insecticides, herbicides, and fungicides for use by a variety of farmers. In

More information

Digi International, Inc.

Digi International, Inc. Feltl and Company Research Department 225 South Sixth Street, Suite 4200 Minneapolis, MN 55402 1.866.655.3431 Jay M. Meier jmmeier@feltl.com 612.492.8847 Digi International, Inc. Company Description: Digi

More information

Vascular Solutions, Inc.

Vascular Solutions, Inc. Vascular Solutions, Inc. Vascular Solutions is a medical device company focused on developing products for the interventional radiology and cardiology markets. Current product offerings include the Duett

More information

MEDNAX, Inc. Better than expected results inline with our propriety research; raising estimates

MEDNAX, Inc. Better than expected results inline with our propriety research; raising estimates MEDNAX, Inc. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN 55402 1.866.655.3431 Matt J. Weight mjweight@feltl.com 612.492.8812 Healthcare Services August 1,

More information

MINE SAFETY APPLIANCES CO. (MSA - $47.98) Initiating Coverage BUY Aggressive

MINE SAFETY APPLIANCES CO. (MSA - $47.98) Initiating Coverage BUY Aggressive Richard A. Ryan raryan@feltl.com (612) 492-8841 Safety Equipment Manufacturer August 20, 2003 Financial Summary Rev 2002 2003E 2004E (mil) March $128.1 $160.4A $175.1E June $141.9 $175.9A $192.0E Sept.

More information

Synovis Life Technologies, Inc. (SYNO - $17.89) HOLD. Dennis E. Nielsen, CFA (612)

Synovis Life Technologies, Inc. (SYNO - $17.89) HOLD. Dennis E. Nielsen, CFA (612) Dennis E. Nielsen, CFA denielsen@feltl.com (612) 492-8806 Medical Devices June 2, 2003 Financial Summary Rev (mil) 2002 2003E 2004E Jan $8.0 $12.5A Apr $9.5 $15.3A Jul $10.7 $14.0E Oct $11.8 $14.5E FY

More information

Vascular Solutions, Inc. (VASC - $9.21)

Vascular Solutions, Inc. (VASC - $9.21) Medical Devices March 23, 2005 Financial Summary Rev(mil) 2004 2005E 2006E Mar $4.4 $7.0E $ Jun $5.2 $7.6E $ Sep $5.9 $8.6E $ Dec $6.7 $9.9E $ FY $22.3 $33.0E $45.0E P/Sales 5.9x 4.0x 2.9x EPS 2004 2005E

More information

Electronic Arts Inc. EA NASDAQ Neutral-2 Good 2Q Results; Neutral Rating Based on Stock Valuation

Electronic Arts Inc. EA NASDAQ Neutral-2 Good 2Q Results; Neutral Rating Based on Stock Valuation COMPANY UPDATE / ESTIMATE CHANGE Key Metrics EA - NASDAQ (as of 10/31/17) $119.60 Two Year Price Target N/A 52-Week Range $73.74 - $122.79 Shares Outstanding (mil) 309 Market Cap. ($mil) $36,956 3-Mo.

More information

DexCom, Inc. (DXCM - $15.73) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN

DexCom, Inc. (DXCM - $15.73) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN DexCom, Inc. Company Description: DexCom is a real-time diagnostics medical device company focused on the continuous glucose monitoring (CGM) market for both diabetics and critical care patients. The company

More information

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5 COMPANY UPDATE ESTIMATE CHANGE Key Metrics FELE - NASDAQ - as of 2/20/18 $39.85 Price Target -- 52-Week Range $36.00 - $47.20 Shares Outstanding (mm) 46.6 Market Cap. ($mm) $1,856.9 1-Mo. Average Daily

More information

DexCom, Inc. (DXCM - $14.30) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN

DexCom, Inc. (DXCM - $14.30) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN DexCom, Inc. Company Description: DexCom is a real-time diagnostics medical device company focused on the continuous glucose monitoring (CGM) market for both diabetics and critical care patients. The company

More information

DaVita Inc. (DVA - $119.21) BUY. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN

DaVita Inc. (DVA - $119.21) BUY. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN DaVita Inc. Company Description: DaVita Inc. provides dialysis services for patients suffering from chronic kidney failure, which is known as end stage renal disease (ESRD) in the United States. Feltl

More information

Research Report- Update

Research Report- Update The Standard of Excellence in the Microcap Market Member: NASD, SIPC Buy Research Report- Update Robert C. Schroeder UFP Technologies, Inc. May 15, 2000 Ticker: UFPT--$2.56 (NASDAQ) FY1997 FY1998 FY1999A

More information

DexCom, Inc. Tickled pink Q3 EPS less red than our estimate and new G4 color choice

DexCom, Inc. Tickled pink Q3 EPS less red than our estimate and new G4 color choice DexCom, Inc. Company Description: DexCom is a real-time diagnostics medical device company focused on the continuous glucose monitoring (CGM) market for both diabetics and critical care patients. The company

More information

AutoZone, Inc. EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Quick Read: Sales a Bit Soft, But Results Solid. September 22, 2016

AutoZone, Inc. EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Quick Read: Sales a Bit Soft, But Results Solid. September 22, 2016 EQUITY RESEARCH QUARTERLY UPDATE September 22, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $900.00 AZO - NYSE $751.45 3-5 Yr. EPS Gr. Rate 14% 52-Wk Range $819.54-$681.01 Shares Outstanding 30.8M

More information

Electronic Arts Inc. EA NASDAQ Neutral-2 Fiscal 3Q Results Don t Tell the Story of Bright Future, Long-term Growth Prospects

Electronic Arts Inc. EA NASDAQ Neutral-2 Fiscal 3Q Results Don t Tell the Story of Bright Future, Long-term Growth Prospects COMPANY UPDATE / ESTIMATE CHANGE Key Metrics EA - NASDAQ (as of 1/30/18) $118.70 Current intra-day price (1/31/18) $127.81 Two Year Price Target N/A 52-Week Range $80.40 - $122.79 Shares Outstanding (mil)

More information

SodaStream Follow-Up: 1Q Results Better Than Expected; Guidance Raised; Wal-Mart!!!

SodaStream Follow-Up: 1Q Results Better Than Expected; Guidance Raised; Wal-Mart!!! EQUITY RESEARCH COMPANY UPDATE May 9, 2012 Stock Rating: OUTPERFORM 12-18 mo. Price Target $55.00 SODA - NASDAQ $36.90 3-5 Yr. EPS Gr. Rate 30% 52-Wk Range $79.72-$27.60 Shares Outstanding 19.9M Float

More information

Activision Blizzard, Inc. ATVI NASDAQ Underperform-2

Activision Blizzard, Inc. ATVI NASDAQ Underperform-2 COMPANY UPDATE / ESTIMATE CHANGE Key Metrics ATVI - NASDAQ (as of 8/4/17) $62.01 Price Target N/A 52-Week Range $35.12 - $64.06 Shares Outstanding (mil) (basic) 754 Market Cap. ($mil) $46,756 3-Mo. Average

More information

Note Important Disclosures on Pages 6-7 Note Analyst Certification on Page 6

Note Important Disclosures on Pages 6-7 Note Analyst Certification on Page 6 COMPANY UPDATE / ESTIMATE CHANGE Key Metrics GOOGL - NASDAQ - as 4/23/18 $1,073.81 Price Target $1,100 52-Week Range $866.11 - $1,198.00 Diluted Shares Outstanding (mil) 703.5 Market Cap. ($mil) 1-Mo.

More information

Kona Grill, Inc. (KONA - $11.28) Initiating Coverage Growth

Kona Grill, Inc. (KONA - $11.28) Initiating Coverage Growth Mark W. Moeller mwmoeller@feltl.com (612) 492-8849 Upscale Casual Restaurants September 30, 2005 Financial Summary Rev(mil) 2004A 2005E 2006E Mar $5.3 $8.0A $10.3E Jun $5.6 $8.9A $11.5E Sep $6.6 $9.0E

More information

Alphabet Inc. GOOGL - NASDAQ Neutral -1

Alphabet Inc. GOOGL - NASDAQ Neutral -1 COMPANY UPDATE / ESTIMATE CHANGE / TARGET CHANGE Key Metrics GOOGL - NASDAQ - as of 10/30/17 $1,033.13 Price Target $1,100 52-Week Range $743.59 - $1,063.62 Diluted Shares Outstanding (mil) 703.5 Market

More information

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5 COMPANY UPDATE / TARGET CHANGE ESTIMATE CHANGE Key Metrics SR - NYSE - as of 8/1/17 $73.40 Price Target $90.00 52-Week Range $59.54 - $73.70 Shares Outstanding (mm) 48.3 Market Cap. ($mm) $3,542.2 1-Mo.

More information

BTO: Q2/15 Earnings Preview

BTO: Q2/15 Earnings Preview B2Gold Corp. (BTO-T: C$1.69), (BTG-N: US$1.31) August 13, 2015 BUY, High Risk Dundee target: C$2.75 BTO: Q2/15 Earnings Preview Joseph Fazzini, CPA, CA, CFA / (647) 428-8248 jfazzini@dundeecapitalmarkets.com

More information

Company Report. TCL Comm (2618 HK) Strong FY15E ahead backed by solid product roadmap in smartphone/wearables/apps/cloud; Reiterate BUY BUY

Company Report. TCL Comm (2618 HK) Strong FY15E ahead backed by solid product roadmap in smartphone/wearables/apps/cloud; Reiterate BUY BUY Company Report China Merchants Securities (HK) Co.Ltd. Hong Kong Equity Research TCL Comm (2618 HK) Strong FY15E ahead backed by solid product roadmap in smartphone/wearables/apps/cloud; Reiterate BUY

More information

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit

O'Reilly Automotive, Inc. Quick Read: Weather Likely Weighed Upon Sales a Bit EQUITY RESEARCH QUARTERLY UPDATE July 27, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $300.00 ORLY - NASDAQ $277.51 3-5 Yr. EPS Gr. Rate 18% 52-Wk Range $284.66-$225.12 Shares Outstanding 99.4M

More information

Oramed Pharmaceuticals Inc. (ORMP $7.21*)

Oramed Pharmaceuticals Inc. (ORMP $7.21*) Oramed Pharmaceuticals Inc. (ORMP $7.21*) Healthcare: Specialty Pharmaceuticals Buy; $20.00 PT; $104.2M Market Cap Company Update Tuesday, April 17, 2018 Revenue/EPS for 2Q18 in Line/Beat Estimates; Time

More information

Note Important Disclosures on Pages 6-7 Note Analyst Certification on Page 6.

Note Important Disclosures on Pages 6-7 Note Analyst Certification on Page 6. COMPANY UPDATE / ESTIMATE CHANGE Key Metrics FUN - NYSE (as of 11/2/17) $65.42 Two Year Price Target $77.00 52-Week Range $58.05 - $72.56 Shares Outstanding (mil) (basic) 56.1 Market Cap. ($mil) $3,669

More information

Arcimoto, Inc. FUV - $ NASDAQ Buy

Arcimoto, Inc. FUV - $ NASDAQ Buy Craig Irwin, (646) 358-1910 cirwin@roth.com Annapoorni C.S, CFA, (646) 616-2791 acs@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH December 28, 2018 Cleantech & Industrial

More information

Analyst's Notes. Argus Recommendations

Analyst's Notes. Argus Recommendations Report created Jul 23, 2015 Page 1 OF 5 Boeing manufactures commercial jetliners and military aircraft as well as rotorcraft, electronic and defense systems, missiles, satellites, launch vehicles, and

More information

Alphabet Inc. GOOGL - NASDAQ Neutral -1

Alphabet Inc. GOOGL - NASDAQ Neutral -1 COMPANY UPDATE / TARGET CHANGE ESTIMATE CHANGE Key Metrics GOOGL - NASDAQ - as of 5/1/17 $932.82 Price Target $1,000.00 52-Week Range $672.66 - $935.82 Diluted Shares Outstanding (mil) 702.0 Market Cap.

More information

Stryker Corp. Post-4Q15 Thoughts

Stryker Corp. Post-4Q15 Thoughts EQUITY RESEARCH QUARTERLY UPDATE January 27, 2016 Stock Rating: PERFORM 12-18 mo. Price Target $104.00 SYK - NYSE $96.02 3-5 Yr. EPS Gr. Rate 9% 52-Wk Range $105.34-$86.68 Shares Outstanding 378.4M Float

More information

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance

HOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and

More information

1 st Quarter 2016 Earnings Conference Call Transcript

1 st Quarter 2016 Earnings Conference Call Transcript 1 st Quarter 2016 Earnings Conference Call Transcript May 4, 2016 Overview*: BDC reported 1Q16 consolidated revenues of $543.8M. On a year-over-year basis, EBITDA margins of 16.4% increased 90 basis points

More information

Arcimoto, Inc. FUV - $ NASDAQ Buy

Arcimoto, Inc. FUV - $ NASDAQ Buy Craig Irwin, (646) 358-1910 cirwin@roth.com Annapoorni C.S, CFA, (646) 616-2791 acs@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH February 15, 2019 Cleantech & Industrial

More information

The Ensign Group, Inc. (NASDAQ:ENSG)

The Ensign Group, Inc. (NASDAQ:ENSG) The Ensign Group, Inc. (NASDAQ:ENSG) ENSG - Thesis Remains Intact; Reiterate MO MARKET OUTPERFORM COMPANY UPDATE Post Acute Care - Facilities February 14, 2013 Kevin Campbell, CFA, Managing Director kcampbell@avondalepartnersllc.com

More information

Sterling Construction Company, Inc. Rating: Hold

Sterling Construction Company, Inc. Rating: Hold ENGINEERING & CONSTRUCTION Richard S. Paget, CFA 212-218-3894 rpaget@morganjoseph.com Christopher Bamman 212-218-3989 cbamman@morganjoseph.com Company Update / Estimates Change May 11, 2006 Key Metrics

More information

Century Plyboards (India)

Century Plyboards (India) : price: EPS: How does our one year outlook change? We continue to maintain our positive stance on Century Plyboards (CPBI) as it is one of the leading players in the organized plywood market and third

More information

UNITEDHEALTH GROUP INC

UNITEDHEALTH GROUP INC 07-16 09-16 11-16 01-17 03-17 05-17 07-17 HEALTHCARE SERVICES Managed Care Market Overweight UNITEDHEALTH GROUP INC (UNH $187.96 Outperform) Expect Strong Q2 + Focus on Early 2018 Commentary Look for solid

More information

3,746 2,551 3, NIM

3,746 2,551 3, NIM 4QFY17 Result Update Institutional Equities Capital First 11 May 2017 Reuters: CAPF.BO; Bloomberg: CAFL IN Net Interest Income Up, But Offset By Elevated Credit Costs Although the net interest income or

More information

Pharming Group NV (OTC: PHGUF) PHARM.AS AEX Buy

Pharming Group NV (OTC: PHGUF) PHARM.AS AEX Buy Scott R. Henry, CFA, (949) 720-7123 shenry@roth.com Sales (800) 933-6830, Trading (800) 933-6820 Healthcare: BioPharmaceuticals COMPANY NOTE EQUITY RESEARCH May 18, 2017 Pharming Group NV (OTC: PHGUF)

More information

Repco Home Finance REPCO IN

Repco Home Finance REPCO IN 11 August 2014 Price: `431 India Banking & Financial Services Company Update BUY Repco Home Finance REPCO IN 12m Price Target: `460 Steady quarter REPCO reported 1Q15 net profit at `248mn, up 11% YoY and

More information

CalAmp Corp. CAMP - $ NASDAQ Buy

CalAmp Corp. CAMP - $ NASDAQ Buy Scott W. Searle, CFA, (646) 616-2782 ssearle@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH June 28, 2018 Technology: Communications, Wireless & IoT CalAmp Corp. CAMP

More information

AAON, Inc. (AAON) NEUTRAL Price Target: $33 Price: $ Sidoti & Company, LLC

AAON, Inc. (AAON) NEUTRAL Price Target: $33 Price: $ Sidoti & Company, LLC November 1, 2018 Intraday Note Raise Earnings Estimates; Earnings Release AAON, Inc. (AAON) Equity Research Increase 2019 EPS Estimate After This Morning s Solid 3Q:18 Report; 3Q:18 EPS Of $0.27 Beat Our

More information

Analyst's Notes. Argus Recommendations

Analyst's Notes. Argus Recommendations Report created Jan 17, 2018 Page 1 OF 5 Citigroup is one of world's largest banks, with global consumer banking, corporate banking, and investment banking operations. Of the largest U.S. banks, Citigroup

More information

Darden Restaurants, Inc.

Darden Restaurants, Inc. Darden Restaurants, Inc. DRI: Reports Solid Performance; Expectations Were Pretty High Despite Evidence Segment Is Slowing Our View: We reiterate our OW rating following shares coming under pressure because

More information

Note Important Disclosures on Pages 5-6 Note Analyst Certifications on Page 5

Note Important Disclosures on Pages 5-6 Note Analyst Certifications on Page 5 COMPANY UPDATE / ESTIMATE CHANGE Key Metrics WGL - NYSE - as of 2/7/18 $85.41 Price Target -- 52-Week Range $81.59 - $86.89 Shares Outstanding (mm) 51.4 Market Cap. ($mm) $4,386.0 1-Mo. Average Daily Volume

More information

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ)

Small-Cap Research. Atossa Genetics (ATOS-NASDAQ) Small-Cap Research August 15, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ) ATOS: Record revenue reported in 2Q13

More information

Small-Cap Research. Integral Technologies, Inc. (ITKG-OTC) ITKG: Upcoming Revenue Catalysts OUTLOOK SUMMARY DATA ZACKS ESTIMATES

Small-Cap Research. Integral Technologies, Inc. (ITKG-OTC) ITKG: Upcoming Revenue Catalysts OUTLOOK SUMMARY DATA ZACKS ESTIMATES Small-Cap Research November 24, 2015 M. Marin 312-265-9211 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Integral Technologies, Inc. (ITKG-OTC) ITKG: Upcoming Revenue Catalysts Current Recommendation

More information

Century Plyboards (India)

Century Plyboards (India) : price: EPS: How does our one year outlook change? Century Plyboards (India) (CPBI) 2QFY17 revenues grew by 6% yoy driven by 2% yoy growth in plywood products and 11% yoy growth in laminate products.

More information

AutoNation, Inc. AN: Company-Specific Headwinds Continue to Weigh on Results, but Cost Controls are Improving

AutoNation, Inc. AN: Company-Specific Headwinds Continue to Weigh on Results, but Cost Controls are Improving Consumer: Automotive Retail AutoNation, Inc. AN: Company-Specific Headwinds Continue to Weigh on Results, but Cost Controls are Improving Maintaining SW: 1) auto retail industry growth outlook remains

More information

Cummins Inc. Nice Second-Quarter EPS Beat but Not Immune to Second-Half Slowdown. Equity Research Global Industrial Infrastructure Capital Goods

Cummins Inc. Nice Second-Quarter EPS Beat but Not Immune to Second-Half Slowdown. Equity Research Global Industrial Infrastructure Capital Goods Equity Research Global Industrial Infrastructure Capital Goods August 02, 2016 Cummins Inc. Nice Second-Quarter EPS Beat but Not Immune to Second-Half Slowdown Summary/Quick take. Cummins reported a solid

More information

INSTITUTIONAL RESEARCH Technology COMPANY UPDATE Member FINRA/SIPC

INSTITUTIONAL RESEARCH Technology COMPANY UPDATE Member FINRA/SIPC INSTITUTIONAL RESEARCH Technology COMPANY UPDATE Member FINRA/SIPC Toll Free: 561-391-5555 www.dawsonjames.com 1 North Federal Highway - Suite 500 Boca Raton, FL 33432 Pareteum (NYSE American/TEUM) BUY

More information

STEC Inc. Bringing Out the Big Gun--2H Contract Ups Visibility, Ests, PT, Everything

STEC Inc. Bringing Out the Big Gun--2H Contract Ups Visibility, Ests, PT, Everything EQUITY RESEARCH COMPANY UPDATE July 16, 2009 Stock Rating: OUTPERFORM 12-18 mo. Price Target $45.00 STEC - OTC $27.59 3-5 Yr. EPS Gr. Rate 105% 52-Wk Range $28.37-$3.42 Shares Outstanding 48.4M Float 31.7M

More information

Synthetic Biologics (SYN) Rating: Buy

Synthetic Biologics (SYN) Rating: Buy Earnings Update Healthcare August 15, 2013 h (SYN) Rating: Buy Andrew S. Fein 212-356-0546 afein@hcwco.com Continue to View Trimesta Deal in Multiple Sclerosis as NT Value Driver: Reiterate BUY and $4

More information

Aveda Transportation and Energy Services Inc. (AVE-V)

Aveda Transportation and Energy Services Inc. (AVE-V) Aveda Transportation and Energy Services Inc. (AVE-V) Strong Q3 Results Driven by Impressive US Growth November 5, 2013 Michael Mills, CFA (902) 425-8897 mmills@beaconsecurities.ca Aveda reported inline

More information

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile:

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile: 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: 3608 8000 Research: 3608 8097 Facsimile: 3608 6132 HONG KONG RESEARCH Analyst: Paul Sham 28 th August 2009. BOC HONG KONG (HOLDINGS) LIMITED ( 中銀香港 )

More information

The Medicines Company Model Update; Busy Catalyst Calendar Ahead

The Medicines Company Model Update; Busy Catalyst Calendar Ahead EQUITY RESEARCH QUARTERLY UPDATE March 23, 2016 Stock Rating: PERFORM 12-18 mo. Price Target NA MDCO - NASDAQ $31.48 3-5 Yr. EPS Gr. Rate NA 52-Wk Range $43.79-$25.27 Shares Outstanding 68.9M Float 67.1M

More information

Socket Mobile, Inc. (SCKT) NR Price Target: $6 Price: $4.04 Risk Rating: M. Sidoti & Company, LLC

Socket Mobile, Inc. (SCKT) NR Price Target: $6 Price: $4.04 Risk Rating: M. Sidoti & Company, LLC October 27, 2017 Company Sponsored Research Morning Meeting Note Earnings Release Socket Mobile, Inc. (SCKT) Equity Research Maintain $6 Price Target; Robust Demand From Application Developer, Despite

More information

STMicroelectronics N.V.

STMicroelectronics N.V. ENN Europe France Semiconductors 11 Aug 2004 Deutsche Bank STMicroelectronics N.V. Reiterate cautious industry stance and lowering price target Recommendation Buy Price at 11 Aug 2004 EUR 13.94 Target

More information

Calgon Carbon Corporation Rating: Hold

Calgon Carbon Corporation Rating: Hold WATER COMPANIES Christopher Bamman 212-218-3989 cbamman@morganjoseph.com Richard S. Paget, CFA 212-218-3894 rpaget@morganjoseph.com Company Update / Estimates Change February 25, 2008 Key Metrics CCC -

More information

Allscripts Healthcare Solutions, Inc.

Allscripts Healthcare Solutions, Inc. HEALTHCARE: Healthcare Technology Company Update / Estimates Change Allscripts Healthcare Solutions, Inc. MDRX: Continuing the String of Bookings We reiterate our SW rating on Allscripts (MDRX) due to

More information

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188

BHEL SELL RESULTS REVIEW 1QFY15 13 AUG CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188 RESULTS REVIEW 1QFY15 13 AUG 2014 BHEL SELL INDUSTRY CAPITAL GOODS CMP (as on 12 Aug 2014) Rs 224 Target Price Rs 188 Nifty 7,727 Sensex 25,881 KEY STOCK DATA Bloomberg/Reuters BHEL IN/BHEL.BO No. of Shares

More information

BARNES GROUP INC. REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS

BARNES GROUP INC. REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Barnes Group Inc. 123 Main Street Bristol, CT 06010 NEWS RELEASE REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS Sales of $375 million, up 3%; Organic Sales up 1% Operating Margin of 17.0%; Up 120 bps from

More information

Dollarama Inc. Q2 F2017 Preview. (1) Growth expected to continue (2) A deeper look at valuation HIGHLIGHTS. The NBF Daily Bulletin.

Dollarama Inc. Q2 F2017 Preview. (1) Growth expected to continue (2) A deeper look at valuation HIGHLIGHTS. The NBF Daily Bulletin. DOL (T) $97.04 Stock Rating: Outperform (Unchanged) Target: $105.00 (Was $104.00) Risk Rating: Average (Unchanged) Est. Total Return: 8.6% Stock Data: 52-week High-Low (Canada) Bloomberg $98.94 - $66.32

More information

ResMed, Inc. (RMD - $29.84) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN

ResMed, Inc. (RMD - $29.84) HOLD. Feltl and Company Research Department 2100 LaSalle Plaza 800 LaSalle Avenue Minneapolis, MN ResMed, Inc. Company Description: ResMed develops, manufactures and distributes medical equipment for treating, diagnosing, and managing sleep-disordered breathing (SDB) and other respiratory disorders.

More information

CEVA Inc. CEVA - $ NASDAQ Buy

CEVA Inc. CEVA - $ NASDAQ Buy Suji Desilva, CFA, (415) 306-5120 sdesilva@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH August 07, 2018 Semiconductors & IT Hardware CEVA Inc. CEVA - $32.55 - NASDAQ

More information

Savaria Corporation. Q2/17 Results. Span contribution begins; guidance revised (unsurprisingly) upwards HIGHLIGHTS. The NBF Daily Bulletin

Savaria Corporation. Q2/17 Results. Span contribution begins; guidance revised (unsurprisingly) upwards HIGHLIGHTS. The NBF Daily Bulletin SIS (T) $15.06 Stock Rating: Outperform Target: $17.00 Risk Rating: Above Average Est. Total Return 14.6% Stock Data: 52-w eek High-Low $17.55 - $7.74 Bloomberg/Reuters SIS CN / SIS.TO Shares Outstanding

More information

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile:

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile: 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: 3608 8000 Research: 3608 8097 Facsimile: 3608 6132 HONG KONG RESEARCH Analyst: Paul Sham 26 th March 2010. ICBC (ASIA) LIMITED ( 工銀亞洲 ) Sector : Banking

More information

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E

BUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E RAMCO S BUY Target Price: Rs 435 Efforts on cost cutting paying off Q2 EBITDA at Rs 2.8 bn (up 30% YoY) was ahead of our estimates due to lower-than-expected costs. Average costs (excluding freight) declined

More information

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile:

EAST ASIA SECURITIES COMPANY LIMITED 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: Research: Facsimile: 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: 3608 8000 Research: 3608 8097 Facsimile: 3608 6132 HONG KONG RESEARCH Analyst: Vincent Leung 31 st July 2007. HANG SENG BANK LIMITED ( 恒生銀行 ) Sector

More information

Suzlon Energy Ltd RESULT UPDATE 16th August, 2017

Suzlon Energy Ltd RESULT UPDATE 16th August, 2017 RESULT UPDATE 16 th August, 2017 Aug-16 Oct-16 Dec-16 Feb-17 Apr-17 Jun-17 Aug-17 Please vote for us in Asiamoney Brokers Poll 2017: https://www.euromoney.com/article/b13j49qfcr6j pp/asiamoney-brokers-poll-2017-vote-now

More information

SodaStream Follow-Up: Very Strong 4Q Results Reflect Broad-Based Growth; Estimates Raised

SodaStream Follow-Up: Very Strong 4Q Results Reflect Broad-Based Growth; Estimates Raised EQUITY RESEARCH COMPANY UPDATE March 1, 2011 Stock Rating: OUTPERFORM 12-18 mo. Price Target $48.00 SODA - NASDAQ $39.68 3-5 Yr. EPS Gr. Rate 30% 52-Wk Range $46.88-$20.00 Shares Outstanding 19.2M Float

More information

Detour Gold Corporation (DGC-T)

Detour Gold Corporation (DGC-T) Detour Gold Corporation (DGC-T) Q2 Results Advancing Towards Full Production August 6, 2014 Michael Curran, CFA (416) 507-3950 mcurran@beaconsecurities.ca Detour Gold s focus is the continuing ramp up

More information

Credit Suisse 6 th Annual Industrials Conference November 2018

Credit Suisse 6 th Annual Industrials Conference November 2018 Credit Suisse 6 th Annual Industrials Conference November 2018 Safe Harbor This presentation includes forward-looking statements which are statements that are not historical facts, including statements

More information

Investor Deck December 2018

Investor Deck December 2018 Investor Deck December 2018 Safe Harbor This presentation includes forward-looking statements which are statements that are not historical facts, including statements that relate to the mix of and demand

More information

Dollarama Inc. Q4 F2017 Results. A straight-forward beat and other notable business updates HIGHLIGHTS. The NBF Daily Bulletin.

Dollarama Inc. Q4 F2017 Results. A straight-forward beat and other notable business updates HIGHLIGHTS. The NBF Daily Bulletin. DOL (T) $110.88 Stock Rating: Outperform (Unchanged) Target: $122.00 (Was $113.00) Risk Rating: Below Average (Unchanged) Est. Total Return: 10.4% Stock Data: 52-week High-Low (Canada) Bloomberg $104.94

More information

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5

Note Important Disclosures on Pages 5-6 Note Analyst Certification on Page 5 COMPANY UPDATE / ESTIMATE CHANGE Key Metrics COP - NYSE - as of 7/27/17 $44.66 Price Target $65.00 52-Week Range $38.80 - $53.17 Shares Outstanding (mm) 1248.7 Market Cap. ($mm) 1-Mo. Average Daily Volume

More information

J&P Avax. Hefty upside, but no catalysts. Greece, Construction. June 4, 2010

J&P Avax. Hefty upside, but no catalysts. Greece, Construction. June 4, 2010 Greece, Construction J&P Avax Hefty upside, but no catalysts June 4, 2010 Current price 1.45 Target price 5.40 From 6.50 Upside potential 272.4% Remains Outperform Key data Reuters code AVAr.AT Bloomberg

More information

HANG SENG BANK LIMITED ( 恒生銀行 )

HANG SENG BANK LIMITED ( 恒生銀行 ) 9/F, 10 Des Voeux Road Central, Hong Kong. Dealing: 3608 8000 Research: 3608 8097 Facsimile: 3608 6132 HONG KONG RESEARCH Analyst: Kevin Tam 1 st August 2006 HANG SENG BANK LIMITED ( 恒生銀行 ) Sector : Banking

More information

Please see pages 8 and 9 of this publication for important certification and disclosure information.

Please see pages 8 and 9 of this publication for important certification and disclosure information. Industry: Financial Services GICS Sector/ Sub code: Financials Sector / Banks (GIC Code: 40 / Sub code: 4010) Company Summary: Lending Club ( LC, or the Company) is the world s largest online marketplace

More information

Dr Reddy s Laboratories

Dr Reddy s Laboratories : price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia

More information

CALAVO GROWERS, INC. ANNOUNCES FISCAL 2017 FOURTH QUARTER AND FULL-YEAR RESULTS

CALAVO GROWERS, INC. ANNOUNCES FISCAL 2017 FOURTH QUARTER AND FULL-YEAR RESULTS For: Contact: Calavo Growers, Inc. Lee E. Cole Chairman, President and CEO (805) 525-1245 CALAVO GROWERS, INC. ANNOUNCES FISCAL 2017 FOURTH QUARTER AND FULL-YEAR RESULTS ----------------------- Fourth

More information

Comcast EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Comcast 2Q16 Follow-Up: Raising Price Target to $74, 8x 2017E EBITDA.

Comcast EQUITY RESEARCH QUARTERLY UPDATE OUTPERFORM. Comcast 2Q16 Follow-Up: Raising Price Target to $74, 8x 2017E EBITDA. EQUITY RESEARCH QUARTERLY UPDATE July 29, 2016 Stock Rating: OUTPERFORM 12-18 mo. Price Target $74.00 CMCSA - NASDAQ $67.86 3-5 Yr. EPS Gr. Rate 17% 52-Wk Range $68.36-$50.01 Shares Outstanding 2,446.0M

More information

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015

Marico Kaya BUY RESULTS REVIEW 4QFY15 29 APR 2015 RESULTS REVIEW 4QFY15 29 APR 2015 Marico Kaya INDUSTRY FMCG CMP (as on 28 Apr 2015) Rs 1,635 Target Price Rs 1,823 Nifty 8,240 Sensex 27,226 KEY STOCK DATA Bloomberg MAKA IN No. of Shares (mn) 13 MCap

More information

Analyst's Notes. Argus Recommendations

Analyst's Notes. Argus Recommendations Report created Jan 24, 2018 Page 1 OF 5 General Electric is one of the largest publicly traded companies in the world and is classified as a diversified industrials business. The stock is a component of

More information

CLICK TO EDIT MASTER TITLE STYLE Market Perspective

CLICK TO EDIT MASTER TITLE STYLE Market Perspective Market Perspective Global Earnings Remain Supportive November 8, 2017 Keith Lerner, CFA, CMT Managing Director, Chief Market Strategist 2017 SunTrust Banks, Inc. SunTrust is a federally registered service

More information

FAB UNIVERSAL CORPORATION $150M Hidden Value

FAB UNIVERSAL CORPORATION $150M Hidden Value COMPANY UPDATE FAB UNIVERSAL CORPORATION $150M Hidden Value Rob Goldman April 25, 2013 rob@goldmanresearch.com Aaron Schweitzer aaron@goldmanresearch.com FAB UNIVERSAL CORPORATION (NYSE MKT FU - $4.04)

More information

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance

Gillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance 2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings

More information

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,

Key estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20, : price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn

More information

OTC Markets Group Inc. (OTCM) NR Price Target: $30 Price: $29.80 Risk Rating: H. Sidoti & Company, LLC

OTC Markets Group Inc. (OTCM) NR Price Target: $30 Price: $29.80 Risk Rating: H. Sidoti & Company, LLC September 29, 2017 Company Sponsored Research Morning Meeting Note Raise Price Target; Raise Earnings Estimates OTC Markets Group Inc. (OTCM) Equity Research Raise Target To $30 (From $27) As We Introduce

More information

Note Important Disclosures on Pages 6 and 7. Note Analyst Certification on Page 6.

Note Important Disclosures on Pages 6 and 7. Note Analyst Certification on Page 6. COMPANY UPDATE / ESTIMATE CHANGES Key Metrics IRET - NASDAQ (as of 12/11/2017) $5.88 Price Target N/A 52-Week Range $5.60 - $7.28 Shares & Units Outstanding (mm) 135 Market Cap. ($mm) $794 3-Mo. Average

More information

PEDEVCO Corp PED - $ NYSE:MKT Buy

PEDEVCO Corp PED - $ NYSE:MKT Buy Joe Reagor, (949) 720-7106 jreagor@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH June 23, 2015 Resources: Oilfield Services PEDEVCO Corp PED - $0.50 - NYSE:MKT Buy

More information

TTK Prestige. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail. Target CMP. Rating Rs.

TTK Prestige. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail. Target CMP. Rating Rs. Channel-check takeaways Growth recovery pace sees moderation, competitive headwinds continue to prevail Growth traction turns subdued in 4Q - Our channel-check interactions on a pan India basis is indicating

More information